3,5-二碘水杨酸锂 | 653-14-5

• 物质功能分类: 有机原料 - 有机金属盐
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3,5-二碘水杨酸锂
• 中文别名: 3,5-二碘邻羟基苯甲酸锂盐一水合物
• CAS: 653-14-5
• 化学式: C7H4I2LiO3
• 分子量: 396.9
• InChiKey: BIHVWCBCLCSAHY-UHFFFAOYSA-N

物化性质

• 熔点：
  >210°C (dec.)
• 溶解度：
  可溶于DMSO（少许）、乙酸乙酯（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  1.92
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• TSCA：
  Yes
• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  29182900,2918290000

SDS

Name:	Lithium 3 5-diiodosalicylate 95% (titr. on the dried substance) Material Safety Data Sheet
Synonym:	Benzoic acid, 2-hydroxy-3,5-diiodo-, monolithium sal
CAS:	653-14-5

Section 1 - Chemical Product MSDS Name:Lithium 3 5-diiodosalicylate 95% (titr. on the dried substance) Material Safety Data Sheet
Synonym:Benzoic acid, 2-hydroxy-3,5-diiodo-, monolithium sal

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
653-14-5	Benzoic acid, 2-hydroxy-3,5-diiodo-,mo	95	211-496-5

Hazard Symbols: XI
Risk Phrases: 36/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea.
Inhalation:
Causes respiratory tract irritation. Can produce delayed pulmonary edema.
Chronic:
Effects may be delayed.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Sweep up, then place into a suitable container for disposal. Avoid generating dusty conditions. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Do not get in eyes, on skin, or on clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 653-14-5: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: white to cream
Odor: none reported
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: Not available.
Solubility in water: Not available.
Specific Gravity/Density: Not available.
Molecular Formula: C7H3I2LiO3
Molecular Weight: 395.84

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide, hydrogen iodide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 653-14-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Benzoic acid, 2-hydroxy-3,5-diiodo-,monolithium salt - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION
Other No information available.

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/38 Irritating to eyes and skin.
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 653-14-5: No information available.
Canada
CAS# 653-14-5 is listed on Canada's DSL List.
CAS# 653-14-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 653-14-5 is listed on the TSCA inventory.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

制备方法

用于细胞膜糖蛋白的溶解。

用途简介

暂无描述。

用途

用于细胞膜糖蛋白的溶解。

文献信息

• Process for producing alpha,alpha-bis (hydroxymethyl )alkanal
  申请人：Konishi Shinichi

  公开号：US20070112221A1

  公开（公告）日：2007-05-17

  The present invention provides a process for producing an α,α-bis(hydroxymethyl)alkanal represented by Formula (II): (wherein R represents an alkyl group, a cycloalkyl group, or an aryl group) which comprises reacting an aldehyde represented by Formula (I): R—CH 2 —CHO  (I) (wherein R has the same meaning as defined above) with formaldehyde in the presence of a basic catalyst and a phase-transfer catalyst.

  本发明提供了一种制备α，α-双（羟甲基）烷醛的方法，其表示为公式（II）：（其中R表示烷基、环烷基或芳基），该方法包括在碱性催化剂和相转移催化剂的存在下，将公式（I）表示的醛：R-CH2-CHO（其中R具有上述定义的相同含义）与甲醛反应。
• Derivatives and analogues of monoethylglycinexylidide and their production and use
  申请人：ABBOTT LABORATORIES

  公开号：EP0437800A1

  公开（公告）日：1991-07-24

  A substituted monoethylglycinexylidide or analogue is disclosed. The xylidide or analogue has the structure of Fig. 1 of the attached drawings where M is CH₂NHCH₂CH₃, CH₂CH₂CH₂CH₃ or CH₂OCH₂CH₃, one of Y¹ and Y² is H and the other is a protein or a fluorescein moiety chemically bonded to the glycinexylidide or analogue moiety. Also disclosed is a method for carrying out immunoassays for MEGX, which has the structure of Fig. 3 of the attached drawings. The method for carrying out immunoassays involves using the foregoing compounds as tracers and immunogens.

  本发明公开了一种取代的单乙基甘氨酸缩水甘油醚或类似物。这种缩水甘油醚或类似物具有附图 1 所示的结构。其中 M 是 CH₂NHCH₂CH₃、CH₂CH₂CH₂CH₃或 CH₂OCH₂CH₃，Y¹ 和 Y² 中的一个是 H，另一个是与甘氨酰糖苷或类似物分子化学键合的蛋白质或荧光素分子。还公开了一种对 MEGX 进行免疫测定的方法，其结构如附图 3 所示。进行免疫测定的方法包括使用上述化合物作为示踪剂和免疫原。
• Optical article comprising an electrically conductive layer, and production method
  申请人：ESSILOR INTERNATIONAL (Compagnie Générale d'Optique)

  公开号：EP2889339A1

  公开（公告）日：2015-07-01

  The present invention relates to a curable antistatic primer composition, comprising: (a) at least one ion conductive polymer able to complex with ionizable salts; (b) at least a cross-linking agent to cross-link with said ion conductive polymer; and (c) at least one ionizable salts selected from Lithium salts; characterized in that, the composition further comprises at least an amorphiser selected from at least a dendritic polymer. The present invention also relates to an optical article having at least one surface comprising an antistatic primer coating obtained by depositing on a substrate and curing said composition, and its production method.

  本发明涉及一种可固化的抗静电底漆组合物，包括 (a) 至少一种能与可离子化的盐络合的离子导电聚合物； (b) 至少一种与所述离子导电聚合物交联的交联剂；以及 (c) 至少一种选自锂盐的可电离盐； 其特征在于，该组合物还包括至少一种选自树枝状聚合物的非晶化剂。 本发明还涉及一种光学制品及其生产方法，该光学制品至少有一个表面包含通过在基底上沉积和固化所述组合物而获得的抗静电底涂层。
• Treating and preventing disease with TMA and TMAO lowering agents
  申请人：The Cleveland Clinic Foundation

  公开号：US10117879B2

  公开（公告）日：2018-11-06

  Provided herein are compositions, systems, and methods for treating a disease, such as kidney and/or cardiovascular disease, with an agent that reduces the production of trimethylamine (TMA) or trimethylamine-n-oxide (TMAO) in a subject. In certain embodiments, the agent is: i) 3,3-dimethyl-1-butanol (DMB) or a DMB derivative or related compound, ii) acetylsalicylic acid or derivative thereof (e.g., with an enteric coating for delivery to the colon and/or cecum); iii) a flavin monooxygenase 3 (FMO3) inhibitor; iv) a gut TMA lyase inhibitor; v) an antibiotic or antimicrobial; vi) a probiotic or prebiotic; vii) an antiplatelet agent; or viii) a TMA and/or TMAO sequestering agent.

  本文提供的组合物、系统和方法用于使用可减少受试者体内三甲胺（TMA）或三甲胺氧化物（TMAO）产生的制剂治疗疾病，如肾脏和/或心血管疾病。在某些实施方案中，药剂是：i) 3,3-二甲基-1-丁醇（DMB）或 DMB 衍生物或相关化合物，ii) 乙酰水杨酸或其衍生物（例如、iii) 黄素单加氧酶 3 (FMO3) 抑制剂；iv) 肠道 TMA 裂解酶抑制剂；v) 抗生素或抗菌剂；vi) 益生菌或益生元；vii) 抗血小板剂；或 viii) TMA 和/或 TMAO 封闭剂。
• Systems and methods for serial flow emulsion processes
  申请人：Dropworks, Inc.

  公开号：US10906038B2

  公开（公告）日：2021-02-02

  Disclosed herein are systems and methods for serial flow emulsion processes. Systems and methods as described herein result in reduced cross-contamination.

  本文公开了用于串联流动乳化工艺的系统和方法。本文所述的系统和方法可减少交叉污染。